The expression of cdmGS17666 under the control of Scer\GAL4drl-P15 leads to lethality during development. Expression under the control of Scer\GAL4GMR.PF does result in any obvious eye phenotypes compared to controls.
cdmGS17666, Scer\GAL4elav.Switch.PO is a non-enhancer of abnormal locomotor behavior | adult stage phenotype of Hsap\ATXN370Q.UAS, Scer\GAL4elav.Switch.PO
cdmGS17666, Scer\GAL4GMR.PF is a suppressor of abnormal eye color phenotype of Hsap\ATXN3tr.Q78.UAS.Tag:HA, Scer\GAL4GMR.PF
cdmGS17666, Scer\GAL4GMR.PF is a suppressor of visible phenotype of Hsap\ATXN3tr.Q78.UAS.Tag:HA, Scer\GAL4GMR.PF
cdmGS17666, Scer\GAL4GMR.PF is a suppressor of increased cell death | adult stage phenotype of Hsap\ATXN3tr.Q78.UAS.Tag:HA, Scer\GAL4GMR.PF
cdmGS17666, Scer\GAL4elav.Switch.PO is a non-suppressor of short lived phenotype of Hsap\ATXN370Q.UAS, Scer\GAL4elav.Switch.PO
cdmGS17666, Scer\GAL4GMR.PF is a suppressor of eye phenotype of Hsap\ATXN3tr.Q78.UAS.Tag:HA, Scer\GAL4GMR.PF
The rough eye phenotype and associated depigmentation and necrosis induced by the expression of Hsap\ATXN3tr.Q78.UAS.Tag:HA under the control of Scer\GAL4GMR.PF are slightly improved by the co-expression of cdmGS17666.
The decreased adult locomotion and decreased lifespan induced by the adulthood-only expression of Hsap\ATXN370Q.UAS under the control of Scer\GAL4elav.Switch.PO and RU-486 treatment are not significantly affected by the co-expression of cdmGS17666.